B. Riley Forecasts Lower Earnings for Denali Therapeutics

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Analysts at B. Riley reduced their Q2 2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research report issued to clients and investors on Wednesday, March 5th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($0.80) per share for the quarter, down from their prior forecast of ($0.79). B. Riley currently has a "Buy" rating and a $35.00 target price on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. B. Riley also issued estimates for Denali Therapeutics' FY2025 earnings at ($2.72) EPS, FY2026 earnings at ($2.48) EPS, FY2027 earnings at ($1.38) EPS and FY2028 earnings at ($2.05) EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08.

A number of other research firms have also recently issued reports on DNLI. William Blair reaffirmed an "outperform" rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Stifel Nicolaus upgraded Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 price target on the stock in a research note on Monday, December 16th. Morgan Stanley began coverage on shares of Denali Therapeutics in a research report on Friday. They set an "overweight" rating and a $33.00 price objective for the company. Robert W. Baird assumed coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price objective on the stock. Finally, HC Wainwright raised their target price on shares of Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $37.20.

Remove Ads

Denali Therapeutics Stock Performance

NASDAQ:DNLI traded up $0.09 during mid-day trading on Friday, hitting $15.04. The stock had a trading volume of 1,753,690 shares, compared to its average volume of 1,010,455. Denali Therapeutics has a twelve month low of $14.01 and a twelve month high of $33.33. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -5.45 and a beta of 1.46. The company's 50 day simple moving average is $20.70 and its 200 day simple moving average is $24.24.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its holdings in shares of Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares in the last quarter. Quest Partners LLC acquired a new stake in Denali Therapeutics in the third quarter valued at about $73,000. GF Fund Management CO. LTD. acquired a new stake in Denali Therapeutics in the fourth quarter valued at about $62,000. Point72 Hong Kong Ltd acquired a new position in Denali Therapeutics during the fourth quarter worth about $65,000. Finally, PNC Financial Services Group Inc. raised its stake in Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after acquiring an additional 885 shares in the last quarter. 92.92% of the stock is owned by institutional investors.

Insider Activity

In other Denali Therapeutics news, CEO Ryan J. Watts sold 29,266 shares of the firm's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the transaction, the chief executive officer now directly owns 260,721 shares of the company's stock, valued at $5,271,778.62. This trade represents a 10.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve E. Krognes sold 3,339 shares of the company's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total transaction of $69,484.59. Following the sale, the director now directly owns 25,757 shares of the company's stock, valued at approximately $536,003.17. This trade represents a 11.48 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 47,940 shares of company stock worth $973,442. 7.90% of the stock is currently owned by company insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.